Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Mayur Madhavan Clear advanced filters

  • A method for generating cortical spheroids from human pluripotent stem cells produces maturing oligodendrocytes that can myelinate axons and model myelin disease and drug effects.

    • Mayur Madhavan
    • Zachary S. Nevin
    • Paul J. Tesar
    Research
    Nature Methods
    Volume: 15, P: 700-706

  • Oligodendrocytes are vulnerable to chemical toxicity during development. However, few environmental chemicals have been identified as potential hazards. Here, the authors discover chemicals in common household products as harmful to oligodendrocyte development.

    • Erin F. Cohn
    • Benjamin L. L. Clayton
    • Paul J. Tesar
    Research
    Nature Neuroscience
    Volume: 27, P: 836-845

  • The isolation and propagation of oligodendroglial cells from postnatal animals can be impractical for functional genetic studies. This study highlights the potential of a new approach to rapidly generate oligodendrocytes and their progenitors from mouse embryonic and induced pluripotent stem cells, independent of mouse strain or mutational status.

    • Angela M. Lager
    • Olivia G. Corradin
    • Paul J. Tesar
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-8

  • In a mouse model of the leukodystrophy Pelizaeus–Merzbacher disease, myelination, motor performance, respiratory function and lifespan are improved by suppressing proteolipid protein expression, suggesting PLP1 as a therapeutic target for human patients with this disease and, more broadly, antisense oligonucleotides as a pharmaceutical modality for treatment of myelin disorders.

    • Matthew S. Elitt
    • Lilianne Barbar
    • Paul J. Tesar
    Research
    Nature
    Volume: 585, P: 397-403